UK markets open in 7 hours 42 minutes

GC Biopharma Corp. (006280.KS)

KSE - KSE Delayed price. Currency in KRW
Add to watchlist
111,900.00+500.00 (+0.45%)
At close: 03:30PM KST

GC Biopharma Corp.

107, Ihyeon-ro 30beon-gil
Giheung-gu
Yongin-Si
South Korea
82 3 1260 9300
https://www.globalgreencross.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Il-Sup Huh Ph.D.Chairman & CEON/AN/A1954
Mr. Eun-Cheol HurPresident & DirectorN/AN/A1972
Mr. Min-Taek LeeSenior Managing Director of SalesN/AN/A1963
Mr. Young Sup HuhExecutive Vice PresidentN/AN/A1941
Mr. In-Jae LeeSenior MD & DirectorN/AN/A1963
Mr. Byeong-Hwa KimVP & DirectorN/AN/A1958
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for hereditary antithrombin-III deficiency; Facnyne inj. for hemophilia B; Fibrinogen to treat hypofibrinogenemia and afibrinogenemia; Gamma Globulin for hypogammaglobulinemia and agammaglobulinemia; GCFLU Quadrivalent and GC FLU pre-filled syringe inj. for prevention of influenza; GreenGene F inj. for bleeding symptom control and hemostasis for persons with hemophilia A; GreenGene inj. for bleeding episodes induced by hemophilia A; Greenplast Q for sealing tissues and closing open wounds; and Green-VIII inj. for Hemophilia A with supplies of blood coagulation factor VIII. In addition, it provides Hepabig inj. for hepatitis B; Histobulin to treat bronchial asthma; Hunterase for hunter syndrome; I.V. Hepabig inj. for prevention of hepatitis B recurrence in patients following liver transplantation; I.V.-Globulin SN inj. 5%; Immuncell-LC to treat liver cancer; Sero-Tet inj. for prophylaxis of tetanus and the reduction of tetanus symptoms; Shinbaro for anti-inflammation, pain relief, and osteoarthritis; Varicella Vaccine-GCC inj. for prophylaxis of varicella; and Varicella-Zoster Immune Globulin-GCC inj. for passive immunity to susceptible immunodeficient children exposed to varicella. The company was founded in 1967 and is headquartered in Yongin-Si, South Korea. GC Biopharma Corp. is a subsidiary of Green Cross Holdings Corporation.

Corporate governance

GC Biopharma Corp.’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.